Neulasta® - Request Contact

Neulasta® (pefgilgrastim). Start with support

Request

Contact

If you have medical, clinical, prescribing, or other practice-related questions regarding Neulasta^®, Amgen is here to answer them. Please complete the form below, and an Amgen representative will do their best to contact you within 1 business day.

Items in BOLD are required

First Name:

Last Name:

Phone:

ext.

Zip Code:

I would like to be contacted about:


	Neulasta^® (pegfilgrastim) is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia. Important Product Safety Information Neulasta^® Prescribing Information \| NEUPOGEN^® (Filgrastim) Prescribing Information \| Medical Information Connection™ \| Site Map \| Amgen.com 2009 Amgen. All rights reserved. This site for use in U.S. only.